Radiolabeled protein-inhibitor peptides with rapid clinical translation towards imaging and therapy

Guillermina Ferro-Flores, Blanca Ocampo-García, Myrna Luna Gutiérrez, Clara Santos Cuevas, Nallely Jiménez-Mancilla, Erika Azorín-Vega, Laura Meléndez-Alafort

Research output: Contribution to journalArticle

Abstract

Protein interactions are the basis for the biological functioning of human beings. However, many of these interactions are also responsible for diseases, including cancer. Synthetic inhibitors of protein interactions based on small molecules are widely investigated in medicinal chemistry. The development of radiolabeled protein-inhibitor peptides for molecular imaging and targeted therapy with quickstep towards clinical translation is an interesting and active research field in the radiopharmaceutical sciences. In this article, recent achievements concerning the design, translational research and theranostic applications of structurally-modified small radiopeptides such as prostate-specific membrane antigen (PSMA) inhibitors, fibroblast activation protein (FAP) inhibitors and antagonists of chemokine-4 receptor ligands (CXCR-4-L), with high affinity for cancer-associated target proteins, are reviewed and discussed.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalCurrent Medicinal Chemistry
DOIs
Publication statusE-pub ahead of print - Dec 23 2019

    Fingerprint

Cite this

Ferro-Flores, G., Ocampo-García, B., Gutiérrez, M. L., Cuevas, C. S., Jiménez-Mancilla, N., Azorín-Vega, E., & Meléndez-Alafort, L. (2019). Radiolabeled protein-inhibitor peptides with rapid clinical translation towards imaging and therapy. Current Medicinal Chemistry, 1-12. https://doi.org/10.2174/0929867327666191223121211